• Completed

NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM

Updated: Jun 15

Bellini

RRMM

bellini trial

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)


NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in Multiple Myeloma

Suspended (Safety)


This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.


Sponsor

AbbVie


Collaborator

Genentech, Inc.


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT02755597

Official Title:A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors

First Posted : April 29, 2016


Click here for details on ClinicalTrials.gov

 

Venetoclax: National Cancer Institute

Venetoclax: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

 

Drug: Placebo

Drug: Bortezomib

Drug: Dexamethasone

Drug: Venetoclax

 

BELLINI

NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM


Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Lancet Oncol; 2020

https://pubmed.ncbi.nlm.nih.gov/33129376/



84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Hematology Disease Topics & Pathways:

Clinical Trials, Adults, Non-Biological, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies, Pharmacology, Study Population

Saturday, December 11, 2021: 10:30 AM

Learn more:

https://ash.confex.com/ash/2021/webprogram/Paper145757.html

 

Locations

United States, Colorado

United States, North Carolina

United States, Ohio

Canada, Ontario

Canada, Quebec

Australia, New South Wales

Australia, Queensland

Australia, South Australia

Australia, Tasmania

Australia, Victoria

Australia, Western Australia

Europe

United Kingdom

France

Germany

Hungary

Ireland

Italy

Spain

Ukraine

South America

Brazil

Asia

Japan

Korea, Republic of

Russian Federation

Taiwan






Posts Archive